The DANTE trial protocol: a randomised phase III trial to evaluate the Duration of ANti-PD-1 monoclonal antibody Treatment in patients with metastatic mElanoma

The DANTE trial protocol: a randomised phase III trial to evaluate the Duration of ANti-PD-1 monoclonal antibody Treatment in patients with metastatic mElanoma

Abstract Background Immunotherapy is revolutionising the treatment of patients diagnosed with melanoma and other cancers. The first immune checkpoint inhibitor, ipilimumab (targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4)), showed a survival advantage over standard chemotherapy. Subseq...

Full description

Bibliographic Details
Main Authors: Oliver Coen, Pippa Corrie, Helen Marshall, Ruth Plummer, Christian Ottensmeier, Jane Hook, Sue Bell, Gurdeep S. Sagoo, David Meads, Janine Bestall, Galina Velikova, Ferdia A. Gallagher, Alexandra Smith, Helen Howard, Ellen Mason, Eszter Katona, Shobha Silva, Michelle Collinson, Simon Rodwell, Sarah Danson
Format: Article
Language:English
Published: BMC 2021-07-01
Series:BMC Cancer
Subjects:
Immunotherapy
Checkpoint inhibitor
Anti-PD-1
Metastatic melanoma
Schedule
Efficacy
Online Access:https://doi.org/10.1186/s12885-021-08509-w

Internet

https://doi.org/10.1186/s12885-021-08509-w

Similar Items